Senti Biosciences, a clinical-stage company, was founded with the mission to create a new generation of smarter medicines for patients living with incurable diseases. Utilizing synthetic biology, Senti Bio designs and optimizes proprietary Gene Circuits, which are novel combinations of DNA sequences that reprogram cells to sense inputs, compute decisions, and respond accordingly. The company's primary focus is on developing differentiated cancer therapeutics, aiming to innovate cell-based therapies that offer more precise and effective treatment options.

Notable affiliated individuals and investors include prominent figures in biotechnology and venture capital. Senti Biosciences has achieved significant milestones, including advancing its programmable biology platform into clinical stages and securing substantial funding to support its research and development efforts. The company's impact is marked by its pioneering approach to cancer therapy, potentially transforming the landscape of treatment for incurable diseases through its innovative use of synthetic biology.